Trial Profile
A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Dec 2021
Price :
$35
*
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 15 Oct 2021 Results from two phase 2 trials in MS presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 06 May 2019 According to a Sanofi Genzyme media release, post-hoc analysis of four clinical studies: a Phase 2 study, Phase III TEMSO, TOWER and TENERE core studies and their extensions, will be presented during the 71st annual meeting of the American Academy of Neurology (AAN) in Philadelphia, PA.
- 12 Oct 2018 Results (n=1779) of pooled post hoc analysis of two phase 3 studies TEMSO and TOPIC and a phase 2 trial, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.